The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Adjuvant pembrolizumab for postnephrectomy renal cell carcinoma (RCC): Expanded efficacy analyses from KEYNOTE-564.
 
Toni K. Choueiri
Employment - Dana Farber Cancer Hospital
Leadership - ASCO; Dana Farber Cancer Hospital; ESMO; KidneyCan; NCCN
Stock and Other Ownership Interests - Osel; Pionyr; Precede Bio; Tempest Therapeutics
Honoraria - Alexion Pharmaceuticals; alligent; Analysis Group; ASCO; AstraZeneca; Aveo; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Clinical Care Options; Corvus Pharmaceuticals; Eisai; EMD Serono; Exelixis; Foundation Medicine; Genentech/Roche; GlaxoSmithKline; Harborside Press; HERON; Ipsen; IQvia; Janssen Oncology; Kidney Cancer Association; Lancet Oncology; Lilly; Lpath; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; NCI Genitourinary Cancers Steering Committee; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Prometheus; Sanofi/Aventis; The New England Journal of Medicine; UpToDate
Consulting or Advisory Role - Alexion Pharmaceuticals; alligent; Analysis Group; Aravive; Arcus Biosciences; ASCO; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Clinical Care Options; Corvus Pharmaceuticals; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; GlaxoSmithKline; Harborside Press; HERON; Infinity Pharmaceuticals; Ipsen; Kanaph Therapeutics; Kidney Cancer Association; Lancet Oncology; Lilly; Lpath; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; NiKang Therapeutics; Novartis; Nuscan Diagnostics; Peloton Therapeutics; Pfizer; PlatformQ Health; Prometheus; Roche/Genentech; Sanofi/Aventis; Tempest Therapeutics; The New England Journal of Medicine; UpToDate
Research Funding - Agensys (Inst); Analysis Group (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celldex (Inst); Cerulean Pharma (Inst); Congressionally Directed Medical Research Programs (DOD) (Inst); Corvus Pharmaceuticals (Inst); Eisai (Inst); Exelixis (Inst); Foundation Medicine (Inst); GATEWAY for Cancer Research (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Merck (Inst); NCI (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Prometheus (Inst); Roche (Inst); Roche/Genentech (Inst); Seattle Genetics/Astellas (Inst); Takeda (Inst); TRACON Pharma (Inst)
Patents, Royalties, Other Intellectual Property - -International Patent Application No. PCT/US2018/058430, entitled “Biomarkers of Clinical Response and Benefit to Immune Checkpoint Inhibitor Therapy (Inst); ctDNA technologies; International Patent Application No. PCT/US2018/12209, entitled “PBRM1 Biomarkers Predictive of Anti-Immune Checkpoint Response (Inst)
Travel, Accommodations, Expenses - Alexion Pharmaceuticals; alligent; Analysis Group; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Clinical Care Options; Corvus Pharmaceuticals; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; GlaxoSmithKline; Harborside Press; HERON; Ipsen; Kidney Cancer Association; Lancet Oncology; Lilly; Lpath; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Prometheus; Roche/Genentech; Sanofi/Aventis; The New England Journal of Medicine; UpToDate
Other Relationship - Medical writing and editorial assistance support may have been funded by Communications companies funded by pharmaceutical companies such as ClinicalThinking, Health Interactions, Envision Pharma Group, Fishawack Group of Companies, Parexel
 
Piotr Tomczak
No Relationships to Disclose
 
Se Hoon Park
Honoraria - Merck; Ono Pharmaceutical; Pfizer
Consulting or Advisory Role - Janssen Oncology
Research Funding - Ono Pharmaceutical; Sanofi
 
Balaji Venugopal
Honoraria - Bristol-Myers Squibb; Eisai; EUSA Pharma; Ipsen; Merck; MSD Oncology; Pfizer
Consulting or Advisory Role - Bristol-Myers Squibb; MSD Oncology; Pfizer/EMD Serono
Speakers' Bureau - Eisai; Janssen Oncology; MSD Oncology; Pfizer
Research Funding - Calithera Biosciences (Inst); Ipsen (Inst); MSD Oncology (Inst); Pfizer/EMD Serono (Inst)
Travel, Accommodations, Expenses - EUSA Pharma; Ipsen
 
Tom Ferguson
Research Funding - AstraZeneca (Inst); Janssen (Inst); MSD (Inst)
Travel, Accommodations, Expenses - BMS; MSD; Roche
 
Stefan N. Symeonides
Consulting or Advisory Role - Bicycle Therapeutics (Inst); Boxer Capital (Inst); Bristol-Myers Squibb (Inst); Duke Street Bio (Inst); Eisai (Inst); Ellipses Pharma (Inst); EUSA Pharma (Inst); MedAnnex (Inst); MSD (Inst); Pfizer/EMD Serono (Inst); Vaccitech (Inst)
Speakers' Bureau - Bristol-Myers Squibb (Inst); EUSA Pharma (Inst); Ipsen (Inst)
Research Funding - BiolineRx (Inst); BioNTech (Inst); Boston Pharmaceuticals (Inst); Incyte (Inst); Merck Sharp & Dohme (Inst); Nouscom (Inst); Nucana (Inst); Roche/Genentech (Inst); Sapience Therapeutics (Inst); Sierra Oncology (Inst); Verastem (Inst)
Travel, Accommodations, Expenses - BioNTech; Bristol-Myers Squibb; Ipsen; MSD
 
Jaroslav Hajek
No Relationships to Disclose
 
Yen-Hwa Chang
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; Ipsen; Janssen; Merck
 
Jae-Lyun Lee
Stock and Other Ownership Interests - Amgen; BeiGene; Black Diamond Therapeutics; Innovent Biologics; Johnson & Johnson/Janssen; Karyopharm Therapeutics; Merck; Myovant Sciences; Zymeworks
Honoraria - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; MSD; Pfizer
Consulting or Advisory Role - AstraZeneca; BMS Korea; GI Innovation; Merck; MSD; Oscotec; Pfizer; Sanofi
Research Funding - Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer Schering Pharma (Inst); Bristol-Myers Squibb (Inst); GI Innovation (Inst); Janssen (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst)
 
Naveed Sarwar
Consulting or Advisory Role - MSD Oncology
Speakers' Bureau - Eusa Pharma; Merck Serono
 
Antoine Thiery-Vuillemin
Honoraria - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Ipsen; Janssen; MSD; Novartis; Pfizer; Roche/Genentech; Sanofi
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Ipsen; Janssen; MSD; Novartis; Pfizer; Roche; Sanofi
Research Funding - Pfizer (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Ipsen; Janssen; MSD; Pfizer; Roche
 
Marine Gross-Goupil
Consulting or Advisory Role - Amgen; amgen; Astellas Medivation; AstraZeneca; Bayer/Onyx; Bristol-Myers Squibb; ipsen; Janssen-Cilag; MSD Oncology; Pfizer; Roche; Sanofi
Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); BMS (Inst); ipsen (Inst); Janssen-Cilag (Inst); Merck (Inst); MSD Oncology (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; AstraZeneca; ipsen; ipsen; ipsen; Janssen-Cilag; pfizer; Roche
Other Relationship - Janssen
 
Mauricio Mahave
No Relationships to Disclose
 
Naomi B. Haas
Consulting or Advisory Role - AVEO; Calithera Biosciences; Eisai; Exelixis; Merck Sharp & Dohme; Pfizer; Roche/Genentech
Expert Testimony - Lilly (I)
 
Piotr Sawrycki
Honoraria - Bristol-Myers Squibb; Novartis
Research Funding - Boehringer Ingelheim (Inst); Chiltern (Inst); G1 Therapeutics (Inst); Gilead Sciences (Inst); Merrimack (Inst); MSD (Inst); PAREXEL/ Puma Biotechnology (Inst); PPD Global (Inst); Regeneron (Inst); Tesaro (Inst)
Travel, Accommodations, Expenses - Pierre Fabre; Roche
 
Howard Gurney
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Ipsen; Janssen-Cilag; Merck Serono; Merck Sharp & Dohme; Pfizer; Roche
Speakers' Bureau - Merck Serono
Travel, Accommodations, Expenses - AstraZeneca
 
Lei Xu
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Kentaro Imai
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Jackie Rogerio
Stock and Other Ownership Interests - Merck
Patents, Royalties, Other Intellectual Property - Patent pending as a Merck emplyee
 
Thomas Powles
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; Exelixis; Incyte; Ipsen; Johnson & Johnson; Merck; Merck Serono; MSD; Novartis; Pfizer; Roche; Seagen
Research Funding - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; Exelixis; Ipsen; Johnson & Johnson; Merck; Merck Serono; MSD; Novartis; Pfizer; Roche; Seagen
Travel, Accommodations, Expenses - AstraZeneca; Ipsen; MSD; Pfizer; Roche